Chemokines: What chemokine is that?  by Mackay, Charles R.
R384 Dispatch
Chemokines: What chemokine is that?
Charles R. Mackay
The discovery of a new and unusual member of the
chemokine family illustrates the importance of
chemoattractant diversity in the regulation of leukocyte
movement through the body. The chemokines are now
divisible into four clearly defined subgroups on the
basis of structural and functional properties.
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Five years ago, very few people knew much about
chemokines. Interest in these small proteins centred on
their role as chemoattractants that recruit phagocytic cells
from the blood to local sites of infection. But with the
recent discovery that human immunodeficiency virus-1
(HIV-1) uses chemokine receptors for entry into cells [1],
the status of chemokines has been raised considerably.
Indeed, the use of chemokine receptors explains the entry
of HIV-1 strains into different types of leukocytes, and
also the resistance to infection, despite repeated exposure,
of individuals who have a mutant form of the chemokine
receptor CCR5. These observations have spurred intense
efforts to develop antagonists of chemokine receptors to
inhibit HIV-1 transmission [2]. Over the last few years,
however, there has been another, more subtle develop-
ment in chemokine research. Steadily, the number of
known chemokines is expanding to form a huge subset of
the cytokines that far outnumbers other cytokine families,
such as the tumor necrosis factor (TNF) family. The large
number and variety of chemokines is indicative of the
importance of these molecules, and suggests that diversity
in the chemokine system, rather than diversity in the
adhesion system, is important for regulating leukocyte
movement through tissues. 
Until recently, only two groups of chemokines had been
characterized. These were termed the CXC and CC fami-
lies according to the presence or absence of an amino acid
(X) between a pair of cysteine residues near the amino ter-
minus of the protein (Fig. 1). Interleukin-8 (IL-8), which
attracts neutrophils, was regarded as the typical CXC
chemokine [3], whereas MCP-1, which attracts monocytes
and T cells, was regarded as the typical CC chemokine
[4]. Now that fast, automated sequencing of human and
mouse genes has become commonplace, numerous other
chemokines have been discovered and the story has
become more complicated. There are now subsets within
the CXC subgroup, including the ‘ELR’ subset, members
of which contain a glutamate–leucine–arginine amino-acid
motif near their amino termini and which attract
neutrophils, IP-10 and Mig, which attract activated T
cells, and stromal-cell-derived factor-1 (SDF-1), which
attracts lymphocytes (Fig. 1). A chemokine discovered
last year, termed lymphotactin, has only a single cysteine
near the amino terminus; this C chemokine appears to
attract lymphocytes [5].
Figure 1
The four families of chemokines are
distinguished by the pattern of cysteine
residues near the amino terminus. The CXC
family has an amino acid between two
cysteines; the CC family has none; the C
family has only one cysteine; and the CX3C
family, which has only one known member,
has three amino acids between two cysteines.
Certain sub-families exist within the CXC and
CC families, which can be distinguished by
sequence similarity and functional properties.
The CX3C chemokine comprises a chemokine
module, related in structure to the other
families, as well as a stalk, a transmembrane
region (TM), and a short cytoplasmic region
(Cyt). The proportions of these components
are not drawn to scale, as the stalk comprises
approximately 75% of the CX3C chemokine.
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The most significant of the newly discovered chemokines
has fundamentally different properties. This chemokine,
termed CX3C chemokine, ‘fractalkine’ [6] or ‘neurotactin’
[7], has three intervening amino acids between the amino-
terminal cysteines (Fig. 1). Just one more chemokine to
add to the list may not seem all that important, but this
new chemokine deviates significantly from the CXC, CC
or C members. The sequence of this chemokine, unlike
that of others which terminate at around 70–80 amino
acids, continues for a further 241 residues. There is an 18-
amino-acid hydrophobic sequence near the carboxyl ter-
minus which is suggestive of a membrane-anchoring
motif; this suggestion was confirmed by the transfection
of cells with CX3C chemokine cDNA and detection of
CX3C protein on the cell surface [6,7]. Thus, the likely
structure of this protein is a chemokine-like domain,
perched on top of a stalk which sticks out from the cell
membrane (Fig. 1). 
What is the function of this CX3C chemokine? Synthesis
of CX3C chemokine, like that of most other chemokines,
is induced during inflammatory reactions. This comes as
no surprise, as the function of chemokines is to attract
leukocytes, particularly in inflammatory settings. However,
the association of CX3C chemokine with the membrane
suggests that it may have interesting functions related to
its immobility that contrast with the properties of the
soluble chemokines. A good possibility is that CX3C
chemokine expressed on the endothelial membrane pro-
vides a signal for circulating leukocytes during leukocyte
extravasation. The exit of leukocytes from the blood is a
multistep process, requiring not only adhesion events but
also a signaling event [8,9]. Chemokines are the prime
candidates for such signaling [8,9], and are known to local-
ize to endothelial surfaces through their capacity to bind
proteoglycans [10]; CX3C chemokine, however, already
comes membrane-bound, and may be specialized for
promoting leukocyte transit from the blood to tissues. 
Interestingly, high levels of CX3C chemokine are made by
endothelial cells, but not by leukocytes, suggesting that it
is of particular importance for leukocyte recruitment from
the blood [6,7], rather than for the attraction of leukocytes
to other leukocytes. Bazan et al. [6] showed that mono-
layers of cells expressing CX3C chemokine could trigger
the adhesion of T cells and monocytes under static condi-
tions. Other chemokines, such as IL-8, mediate adhesion-
triggering of cells under flow [11], but the chemokines
that trigger the adhesion of T cells to endothelium under
flow have not been resolved [12]. CX3C chemokine may
provide this function. 
CX3C chemokine — in its guise as neurotactin — also
appears to play an important role in the response to brain
inflammation [7]. Indeed, the brain contains numerous
cells that express chemokines or chemokine receptors, but
the role of these molecules is poorly understood. The syn-
thesis of CX3C chemokine in the brain is markedly upreg-
ulated during inflammation in both endothelial cells and
microglia. The significance of the expression in microglia
is uncertain; it is possible that membrane-bound CX3C
chemokine may stimulate neighboring cells directly. In
this context, membrane-bound CX3C chemokine may
function in a similar way to other membrane-bound
cytokines, such as TNF or steel factor.
CX3C chemokine may also act as a diffusible chemokine.
Chemoattractants work by generating a gradient from
their source, so allowing appropriate receptor-bearing cells
to discern an increase in chemokine concentration, and to
move in the direction of the gradient. CX3C chemokine
appears to be cleavable, and the chemokine module of the
assembly attracts T cells and monocytes [6,7], and possi-
bly neutrophils [7]. Whether cleavable CX3C chemokine
has an important role in vivo is not yet known. Presumably
CX3C chemokine(s) signals through a seven-transmem-
brane-spanning, G-protein-coupled receptor(s), as virtu-
ally all chemoattractants use this type of receptor, even in
Dictyostelium [13]. A number of new receptors have
recently been reported, and their ligands have been iden-
tified (Table 1). As with the growing number of
chemokines that have been identified, the growing
number of chemokine receptors attests to the importance
of this system for regulating leukocyte traffic. Numerous
CC and CXC chemokine receptors have been character-
ized, although the receptors for C and CX3C chemokines
are as yet unknown. Identifying these latter receptors will
be important for understanding various aspects on the
biology of the C and CX3C chemokines. 
Table 1
Chemokine receptors and their ligands.
Receptor Ligands
CCR1 MIP-1a, RANTES, MCP-3, HCC-1?, MPIF-1?
CCR2 MCP-1,3,4
CCR3 Eotaxin, MCP-2,3,4,5, RANTES, MPIF-2
CCR4 TARC
CCR5 RANTES, MIP-1a,b
CCR6 LARC/MIP-3a
CCR7 ELC, MIP-3b
CCR8 I309
CXCR1 IL-8, GCP-2
CXCR2 IL-8, GROa,b,g, Nap-2, ENA-78, GCP-2
CXCR3 IP-10, Mig, I-TAC
CXCR4 SDF-1
? Lymphotactin
? CX3C chemokine
The information contained in this table is derived from numerous
publications, as well as presentations from the recent Keystone
Symposia on The Role of Chemokines in Leukocyte Trafficking and
Disease, held at Copper Mountain, Colorado, April 1997.
The discovery of this fourth type of chemokine raises
questions about the evolutionary history of CX3C and the
other chemokines. The CXC, CC, C and CX3C
chemokine genes map to human chromosomes 4, 17, 1
and 16, respectively. There are some exceptions, for
instance SDF-1 maps to chromosome 10, and this
chemokine may in fact represent a separate chemokine
family [14]. The nature of the primordial chemokine, and
its resemblance to the four known sub-groups of
chemokine, will have to await studies with lower species.
Irrespective of these issues, it is clear that the chemokines
are a diverse and expanding family of molecules, and have
a critical influence on inflammatory processes. Indeed, the
control over leukocyte migration appears to depend more
on the chemokines and their receptors, rather than on the
interactions of the various adhesion molecules. 
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